Which has stronger valuation & earnings, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.37 $181.86M $1.15 63.10 Repligen $785.10M 13.70 $48.89M $0.73 261.16

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Repligen 5.29% 5.30% 3.79%

Does the media favor TECH or RGEN?

In the previous week, Bio-Techne had 9 more articles in the media than Repligen. MarketBeat recorded 11 mentions for Bio-Techne and 2 mentions for Repligen. Bio-Techne's average media sentiment score of 0.74 beat Repligen's score of 0.59 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RGEN or A?

In the previous week, Agilent Technologies had 14 more articles in the media than Repligen. MarketBeat recorded 16 mentions for Agilent Technologies and 2 mentions for Repligen. Agilent Technologies' average media sentiment score of 0.63 beat Repligen's score of 0.59 indicating that Agilent Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, RGEN or BIO?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $785.10M 13.70 $48.89M $0.73 261.16 Bio-Rad Laboratories $2.59B 4.01 $759.90M $8.25 47.04

Does the media refer more to RGEN or BIO?

In the previous week, Bio-Rad Laboratories had 2 more articles in the media than Repligen. MarketBeat recorded 4 mentions for Bio-Rad Laboratories and 2 mentions for Repligen. Repligen's average media sentiment score of 0.59 beat Bio-Rad Laboratories' score of 0.04 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bio-Rad Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, RGEN or DHR?

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $785.10M 13.70 $48.89M $0.73 261.16 Danaher $24.57B 6.40 $3.61B $5.63 39.73

Is RGEN or DHR more profitable?

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 5.29% 5.30% 3.79% Danaher 15.95% 11.04% 6.81%

Does the media refer more to RGEN or DHR?

In the previous week, Danaher had 10 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Danaher and 2 mentions for Repligen. Danaher's average media sentiment score of 0.78 beat Repligen's score of 0.59 indicating that Danaher is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Danaher 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MTD or RGEN?

In the previous week, Mettler-Toledo International had 4 more articles in the media than Repligen. MarketBeat recorded 6 mentions for Mettler-Toledo International and 2 mentions for Repligen. Mettler-Toledo International's average media sentiment score of 1.17 beat Repligen's score of 0.59 indicating that Mettler-Toledo International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Repligen (RGEN) Competitors

$190.65 +6.12 (+3.32%)

Closing price 04:00 PM Eastern

Extended Trading

$193.42 +2.77 (+1.45%)

As of 04:36 PM Eastern

Compare

RGEN vs. TECH, A, BIO, DHR, and MTD

Should you buy Repligen stock or one of its competitors? Repligen's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Repligen compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Repligen	5.29%	5.30%	3.79%

In the previous week, Bio-Techne had 9 more articles in the media than Repligen. MarketBeat recorded 11 mentions for Bio-Techne and 2 mentions for Repligen. Bio-Techne's average media sentiment score of 0.74 beat Repligen's score of 0.59 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.37	$181.86M	$1.15	63.10
Repligen	$785.10M	13.70	$48.89M	$0.73	261.16

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bio-Techne presently has a consensus target price of $68.92, indicating a potential downside of 5.03%. Repligen has a consensus target price of $168.57, indicating a potential downside of 11.58%. Given Bio-Techne's higher possible upside, research analysts clearly believe Bio-Techne is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

Bio-Techne beats Repligen on 12 of the 17 factors compared between the two stocks.

How does Repligen compare to Agilent Technologies?

Repligen (NASDAQ:RGEN) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Repligen presently has a consensus target price of $168.57, indicating a potential downside of 11.58%. Agilent Technologies has a consensus target price of $170.33, indicating a potential downside of 1.55%. Given Agilent Technologies' higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Agilent Technologies	0 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Agilent Technologies had 14 more articles in the media than Repligen. MarketBeat recorded 16 mentions for Agilent Technologies and 2 mentions for Repligen. Agilent Technologies' average media sentiment score of 0.63 beat Repligen's score of 0.59 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Repligen's net margin of 5.29%. Agilent Technologies' return on equity of 24.45% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Agilent Technologies	19.53%	24.45%	13.09%

Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$785.10M	13.70	$48.89M	$0.73	261.16
Agilent Technologies	$7.37B	6.62	$1.30B	$5.08	34.06

97.6% of Repligen shares are held by institutional investors. Comparatively, 87.4% of Agilent Technologies shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Comparatively, 0.2% of Agilent Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Agilent Technologies beats Repligen on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Bio-Rad Laboratories?

Repligen (NASDAQ:RGEN) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Repligen has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Bio-Rad Laboratories had 2 more articles in the media than Repligen. MarketBeat recorded 4 mentions for Bio-Rad Laboratories and 2 mentions for Repligen. Repligen's average media sentiment score of 0.59 beat Bio-Rad Laboratories' score of 0.04 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bio-Rad Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$785.10M	13.70	$48.89M	$0.73	261.16
Bio-Rad Laboratories	$2.59B	4.01	$759.90M	$8.25	47.04

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Bio-Rad Laboratories	8.59%	3.54%	2.48%

97.6% of Repligen shares are held by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Repligen presently has a consensus target price of $168.57, indicating a potential downside of 11.58%. Bio-Rad Laboratories has a consensus target price of $343.33, indicating a potential downside of 11.52%. Given Bio-Rad Laboratories' higher probable upside, analysts clearly believe Bio-Rad Laboratories is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Repligen beats Bio-Rad Laboratories on 9 of the 17 factors compared between the two stocks.

How does Repligen compare to Danaher?

Repligen (NASDAQ:RGEN) and Danaher (NYSE:DHR) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Danaher had 10 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Danaher and 2 mentions for Repligen. Danaher's average media sentiment score of 0.78 beat Repligen's score of 0.59 indicating that Danaher is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Danaher	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen presently has a consensus price target of $168.57, suggesting a potential downside of 11.58%. Danaher has a consensus price target of $230.23, suggesting a potential upside of 2.93%. Given Danaher's higher possible upside, analysts plainly believe Danaher is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Danaher	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$785.10M	13.70	$48.89M	$0.73	261.16
Danaher	$24.57B	6.40	$3.61B	$5.63	39.73

97.6% of Repligen shares are held by institutional investors. Comparatively, 79.1% of Danaher shares are held by institutional investors. 0.6% of Repligen shares are held by company insiders. Comparatively, 10.8% of Danaher shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Danaher	15.95%	11.04%	6.81%

Repligen has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Danaher has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Danaher beats Repligen on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Repligen (NASDAQ:RGEN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Mettler-Toledo International currently has a consensus target price of $1,446.36, indicating a potential downside of 4.86%. Repligen has a consensus target price of $168.57, indicating a potential downside of 11.58%. Given Mettler-Toledo International's higher possible upside, equities research analysts plainly believe Mettler-Toledo International is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.13B	7.37	$869.19M	$44.43	34.22
Repligen	$785.10M	13.70	$48.89M	$0.73	261.16

Mettler-Toledo International has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Repligen	5.29%	5.30%	3.79%

In the previous week, Mettler-Toledo International had 4 more articles in the media than Repligen. MarketBeat recorded 6 mentions for Mettler-Toledo International and 2 mentions for Repligen. Mettler-Toledo International's average media sentiment score of 1.17 beat Repligen's score of 0.59 indicating that Mettler-Toledo International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mettler-Toledo International beats Repligen on 10 of the 17 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGEN vs. The Competition

Export

Metric	Repligen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.76B	$10.81B	$7.26B	$13.10B
Dividend Yield	N/A	1.45%	2.52%	12.57%
P/E Ratio	261.16	75.73	274.73	25.76
Price / Sales	13.70	285.17	679.56	97.70
Price / Cash	54.66	27.90	77.80	52.76
Price / Book	5.09	6.06	10.52	6.34
Net Income	$48.89M	$56.67B	$3.49B	$360.00M
7 Day Performance	6.99%	3.76%	-1.10%	-0.13%
1 Month Performance	4.97%	4.02%	-3.42%	-3.45%
1 Year Performance	53.12%	37.42%	15.10%	5.46%

Repligen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGEN Repligen	2.3556 of 5 stars	$190.65 +3.3%	$168.57 -11.6%	+48.9%	$10.76B	$785.10M	261.16	2,000	Positive News
TECH Bio-Techne	3.6302 of 5 stars	$72.47 +0.1%	$68.92 -4.9%	+37.0%	$11.35B	$1.22B	63.02	3,000
A Agilent Technologies	4.0617 of 5 stars	$162.06 +3.6%	$170.33 +5.1%	+31.2%	$44.11B	$6.95B	31.90	18,100
BIO Bio-Rad Laboratories	1.5152 of 5 stars	$376.26 0.0%	$343.33 -8.8%	+33.9%	$10.06B	$2.58B	45.61	7,450	News Coverage
DHR Danaher	3.4174 of 5 stars	$216.12 +2.0%	$228.91 +5.9%	+17.2%	$148.90B	$24.57B	38.39	60,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGEN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Summary

How does Repligen compare to Agilent Technologies?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Summary

How does Repligen compare to Danaher?

Summary

How does Repligen compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Is TECH or RGEN more profitable?

Does the media favor TECH or RGEN?

Which has stronger valuation & earnings, TECH or RGEN?

Do institutionals and insiders have more ownership in TECH or RGEN?

Do analysts prefer TECH or RGEN?

Which has more volatility & risk, TECH or RGEN?

Summary

How does Repligen compare to Agilent Technologies?

Do analysts recommend RGEN or A?

Does the media favor RGEN or A?

Which has more risk and volatility, RGEN or A?

Is RGEN or A more profitable?

Which has stronger valuation and earnings, RGEN or A?

Do institutionals & insiders have more ownership in RGEN or A?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Which has more risk & volatility, RGEN or BIO?

Does the media refer more to RGEN or BIO?

Which has higher valuation and earnings, RGEN or BIO?

Is RGEN or BIO more profitable?

Do institutionals and insiders have more ownership in RGEN or BIO?

Do analysts rate RGEN or BIO?

Summary

How does Repligen compare to Danaher?

Does the media refer more to RGEN or DHR?

Do analysts rate RGEN or DHR?

Which has stronger valuation and earnings, RGEN or DHR?

Do institutionals and insiders have more ownership in RGEN or DHR?

Is RGEN or DHR more profitable?

Which has more volatility & risk, RGEN or DHR?

Summary

How does Repligen compare to Mettler-Toledo International?

Do insiders & institutionals have more ownership in MTD or RGEN?

Do analysts recommend MTD or RGEN?

Which has preferable valuation & earnings, MTD or RGEN?

Which has more risk & volatility, MTD or RGEN?

Is MTD or RGEN more profitable?

Does the media refer more to MTD or RGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools